It hasn’t been a smooth year for the two pharma giants, but events in the fourth quarter widened the gap between them.

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...

The female hormone estrogen appears to promote binge drinking in women, a new mouse study published recently in the journal ...

Gain Therapeutics' GT-02287 shows promise in treating Parkinson's disease, with positive results and potential for market ...

We recently published a list of 8 Best Low Volatility Stocks To Buy Right Now. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best low ...

New Delhi: Eli Lilly’s Zepbound drug holds potential to dominate the global obesity market due to its superior efficacy and ...

Huminsulin is used for adult and pediatric patient with Type 1 and Type 2 diabetes mellitus that aids in regulation of blood ...

Lupin Ltd. acquires Huminsulin range from Eli Lilly, strengthening its position in the Indian diabetes market.

Given Wegovy’s success and record-high sales, a wave of investments has gone into the obesity space over the last couple of ...

There is a significant Indian population affected with diabetes for both Type 1 and Type 2 Diabetes Mellitus, where Insulin ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

Driven by higher sales, pharmaceutical giant Lupin Ltd. reported a strong 74.1 per cent year-over-year increase in its ...